NO20074710L - 1H-Imidazole derivatives as cannabinoid CB2 receptor modulators - Google Patents

1H-Imidazole derivatives as cannabinoid CB2 receptor modulators

Info

Publication number
NO20074710L
NO20074710L NO20074710A NO20074710A NO20074710L NO 20074710 L NO20074710 L NO 20074710L NO 20074710 A NO20074710 A NO 20074710A NO 20074710 A NO20074710 A NO 20074710A NO 20074710 L NO20074710 L NO 20074710L
Authority
NO
Norway
Prior art keywords
imidazole derivatives
cannabinoid
receptor modulators
receptors
compounds
Prior art date
Application number
NO20074710A
Other languages
Norwegian (no)
Inventor
Herman H Van Stuivenberg
Josephus H M Lange
Bernard J Van Vliet
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of NO20074710L publication Critical patent/NO20074710L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår en gruppe 1H-imidazolderivater som er modulatorer av cannabinoid-CB2-reseptorer, fremgangsmåter for fremstilling av disse forbindelsene, nye intermediater anvendelige ved syntese av nevnte imidazolderivater, fremgangsmåter for fremstilling av disse intermediatene, farmasøytiske sammensetninger som inneholder et eller flere av disse 1H-imidazolderivatene som aktiv ingredies, så vel som anvendelse av disse farmasøytiske sammensetningene for behandling av forstyrrelser hvori cannabinoid-CB2-reseptorer er involvert. Forbindelsene har den generelle formelen (I) hvori R1-R4 har betydningene gitt i foreliggende beskrivelse.The present invention relates to a group of 1H-imidazole derivatives which are modulators of cannabinoid CB2 receptors, processes for the preparation of these compounds, novel intermediates useful in the synthesis of said imidazole derivatives, processes for preparing these intermediates, pharmaceutical compositions containing one or more of them. The 1H-imidazole derivatives as active ingredient, as well as the use of these pharmaceutical compositions for the treatment of disorders involving cannabinoid CB2 receptors. The compounds have the general formula (I) wherein R1-R4 has the meanings given in the present description.

NO20074710A 2005-02-16 2007-09-14 1H-Imidazole derivatives as cannabinoid CB2 receptor modulators NO20074710L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65309105P 2005-02-16 2005-02-16
EP05101171 2005-02-16
PCT/EP2006/060009 WO2006087355A1 (en) 2005-02-16 2006-02-16 1h-imidiazole derivatives as cannabinoid cb2 receptor modulators

Publications (1)

Publication Number Publication Date
NO20074710L true NO20074710L (en) 2007-09-14

Family

ID=36216936

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074710A NO20074710L (en) 2005-02-16 2007-09-14 1H-Imidazole derivatives as cannabinoid CB2 receptor modulators

Country Status (9)

Country Link
EP (1) EP1874734A1 (en)
JP (1) JP2008530179A (en)
AU (1) AU2006215567B2 (en)
BR (1) BRPI0607439A2 (en)
CA (1) CA2597896A1 (en)
IL (1) IL184006A0 (en)
NO (1) NO20074710L (en)
RU (1) RU2410377C2 (en)
WO (1) WO2006087355A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101511796B (en) * 2006-09-05 2012-05-09 协和发酵麒麟株式会社 Imidazole derivative
FR2908766B1 (en) * 2006-11-20 2009-01-09 Sanofi Aventis Sa PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS.
WO2009026407A1 (en) * 2007-08-22 2009-02-26 Allergan, Inc. Pyrrole compounds having sphingosine-1-phosphate receptor agonist or antagonist biological activity
WO2009131957A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US20110237528A1 (en) * 2008-09-19 2011-09-29 Institute For Oneworld Health Compositions and methods comprising imidazole and triazole derivatives
BR112012018631A8 (en) 2010-01-28 2017-12-19 President And Fellows Of Harvard Colege compositions and methods for enhancing proteasome activity
DK2707101T3 (en) 2011-05-12 2019-05-13 Proteostasis Therapeutics Inc PROTEOSTASE REGULATORS
RU2630682C2 (en) * 2011-09-28 2017-09-12 Фуджифилм Корпорэйшн Crystal of 5-hydroxy-1n-imidazol-4-carboxamide& 3/4 hydrate, production method and crystal of 5-hydroxy-1n-imidazol-4-carboxamide hydrate
TW201350119A (en) * 2012-03-29 2013-12-16 Toray Industries Cyclic amine derivatives and pharmaceutical use thereof
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
SG11201510121RA (en) * 2013-06-12 2016-01-28 Kaken Pharma Co Ltd 4-alkynyl imidazole derivative and medicine comprising same as active ingredient
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
KR20180028456A (en) 2015-06-22 2018-03-16 다이닛본 스미토모 세이야꾸 가부시끼가이샤 1,4-disubstituted imidazole derivatives
SG11201710694YA (en) 2015-06-22 2018-01-30 Sumitomo Dainippon Pharma Co Ltd Bicyclic heterocyclic amide derivative
WO2017146128A1 (en) 2016-02-26 2017-08-31 大日本住友製薬株式会社 Imidazolylamide derivative
TW201803869A (en) 2016-04-27 2018-02-01 健生藥品公司 6-aminopyridin-3-yl thiazoles as modulators of ROR[gamma]t
EP3790865A1 (en) 2018-06-18 2021-03-17 Janssen Pharmaceutica NV Phenyl substituted pyrazoles as modulators of roryt
CN112292373A (en) 2018-06-18 2021-01-29 詹森药业有限公司 Pyridylpyrazoles as modulators of ROR γ t
CN112334450A (en) * 2018-06-18 2021-02-05 詹森药业有限公司 Phenyl and pyridyl substituted imidazoles as modulators of ROR γ t
CA3103771A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as modulators of roryt
RU2725878C1 (en) * 2019-12-30 2020-07-07 Федеральное государственное бюджетное учреждение науки Федеральный исследовательский центр "КОМИ научный центр Уральского отделения Российской академии наук" Chiral myrtanyl sulphonamides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004502642A (en) * 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー Cannabinoid receptor modulators, methods for their production, and use of cannabinoid receptor modulators for the treatment of respiratory and non-respiratory diseases
US20110144128A1 (en) * 2005-01-10 2011-06-16 Exelixis, Inc. Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands

Also Published As

Publication number Publication date
IL184006A0 (en) 2007-10-31
WO2006087355A1 (en) 2006-08-24
EP1874734A1 (en) 2008-01-09
AU2006215567A1 (en) 2006-08-24
JP2008530179A (en) 2008-08-07
BRPI0607439A2 (en) 2010-04-06
RU2410377C2 (en) 2011-01-27
CA2597896A1 (en) 2006-08-24
RU2007134428A (en) 2009-03-27
AU2006215567B2 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
NO20074710L (en) 1H-Imidazole derivatives as cannabinoid CB2 receptor modulators
WO2009010871A3 (en) Pyrazole derivatives as antagonists of adenosine a3 receptor
BRPI0607309A2 (en) processes for the preparation of substituted phenylpyrazole urea
UY31796A (en) CONDENSED CYCLOPENTANOCARBOXYL ACID DERIVATIVES SUBSTITUTED WITH ACILAMINE AND ITS USE AS PHARMACEUTICAL PRODUCTS.
NO20051870L (en) 1H-1,2,4-triazole-3-carboxamide derivatives as cannabinoid CB1 receptor ligands
NO20083500L (en) 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive-allosteric modulators of mGluR2 receptors
NO20064456L (en) Thiadiazolidinones as GSK-3 inhibitors
UA103198C2 (en) Squaramide derivatives as cxcr2 antagonists
MX2010007587A (en) Compounds comprising a cyclobutoxy group.
MA34094B1 (en) 3- (HETEROARYLAMINO) -1,2,3,4-TETRAHYDRO-9H-CARBAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE PROSTAGLANDIN D2 RECEPTOR
NO20065678L (en) 3- (4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors.
NO20082285L (en) 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
TW200714587A (en) Biphenyl compounds useful as muscarinic receptor antagonists
EA201190004A1 (en) CONDENSED IMIDAZOLE CARBOXAMIDE AS TRPV3 MODULATORS
NO20091766L (en) Spiro-piperidine
WO2009116074A3 (en) Substituted benzimidazoles as cannabinoid modulator
NO20062249L (en) 1H-imidazole derivatives as cannabionide receptor modulators
WO2007042544A3 (en) Imidazole derivatives and their use for modulating the gabaa receptor complex
WO2008101247A3 (en) 6 ' substituted indole and indazole derivatives having 5-ht6 receptor affinity
EA200870606A1 (en) SERO-CONTAINING DERIVATIVES OF PYRAZOL AS AN ELECTORAL ANTAGONISTS OF CANA CANNABINOID RECEPTOR
WO2010073128A3 (en) Fused imidazole derivatives as trpv3 antagonist
MA32479B1 (en) Compounds new active as muscarinic receptor antagonists
NO20084698L (en) Method for the preparation of indazolyl ureas which inhibit vanilloid receptor subtype 1 (VR1)
TW200640876A (en) 1H-imidazole derivatives as cannabinoid CB2 receptor modulators
MX2007012624A (en) Benzimidazole derivatives and their use for modulating the gabaa receptor complex.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application